Ponvory, a new oral MS treatment, approved for relapsing and active progressive MS

[ActiveMSers]

It'll be ready in April for MSers. These are the other drugs in the same class. Ponvory is the only one tested against another oral.


Sphingosine-1-receptor modulators drugs[edit]

Drugs	Indication	Receptor selectivity	Status
Fingolimod[2]	Multiple sclerosis (MS)	S1P1, S1P3, S1P4 and S1P5	FDA approved 2010, EMA approved 2011
Ozanimod[2]	Multiple sclerosis (MS) and ulcerative colitits (UC)	S1P1 and S1P5	FDA approved 2020
Siponimod[2]	Multiple sclerosis (MS)	S1P1 and S1P5	FDA Approved 2019, EMA approved 2020
Ponesimod[2]	Multiple sclerosis (MS), psoriasis and graft vs. host disease	S1P1	In Phase III clinical trials and Phase II trials. (*)

[ActiveMSers]

Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions


Head-to-head pivotal clinical trial results showed PONVORY™ treatment led to nearly a third fewer annual relapses than teriflunomide

PONVORY™ is the first and only FDA-approved oral disease modifying therapy studied against an established oral comparator

Approval follows more than 10 years of cumulative data demonstrating the treatment's efficacy and safety

---

NEWS PROVIDED BY
Janssen Pharmaceutical Companies of Johnson & Johnson
Mar 19, 2021, 08:09 ET

---

TITUSVILLE, N.J., March 19, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.^1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by over a decade of cumulative clinical research.^3,4,5

PONVORY
The FDA approval is based, in part, on a two-year, head-to-head Phase 3 clinical trial in which PONVORY™ 20 mg demonstrated superior efficacy in significantly reducing annual relapses by 30.5% compared to teriflunomide (Aubagio^®) 14 mg in patients with relapsing MS.³ Over the study period, 71% of patients treated with PONVORY™ had no confirmed relapses, compared to 61% in the teriflunomide group.³ PONVORY™ was also superior to teriflunomidein reducing the number of new gadolinium-enhancing (GdE) T1 lesions and the number of new or enlarging T2 lesions by 59% and 56%, respectively.³ GdE T1 lesions and T2 lesions are identified using magnetic resonance imaging (MRI) technology and are recognized as classic measures of MS pathology that can provide insights into disease activity and disease burden, respectively.^6,7

Click-to-Tweet: #BREAKINGNEWS: @US_FDA approves a new #multiplesclerosis treatment from @JanssenUS proven to help reduce relapses and brain lesions, and backed by over a decade of clinical research. Learn more: http://bit.ly/3vEIS74

PONVORY™ also prevented disability from worsening for most people. Nine in 10 PONVORY™-treated patients did not have worsening of 3-month disability, and PONVORY™ showed a numerical benefit in delaying disability progression. The difference in rates of disability progression was not statistically significant between the PONVORY™ and teriflunomide groups.³

"MS is a complex disease, and any individual's response to MS disease-modifying therapy can vary," said Dr. Bruce Bebo, Executive Vice President of Research at the National MS Society. "It's so important that people living with MS have access to effective treatment options. We are pleased that there is a new therapy approved for relapsing MS."

If treatment needs to be stopped, PONVORY™ leaves the blood within one week, with effects on the immune system wearing off in one to two weeks for most patients.³ This may offer additional flexibility in treatment management if patients need to receive vaccines, address potential infections, or begin family planning. PONVORY™ has no known food restrictions and requires no genetic testing or first-dose monitoring for most patients.³

"In the pivotal study, ponesimod demonstrated superior clinical efficacy in reducing annual relapses and MRI activity compared against teriflunomide, another oral MS therapy. Those results, combined with a favorable side effect profile, make ponesimod a useful treatment option for people with relapsing MS," said Robert J. Fox, M.D., Staff Neurologist, Mellen Center for MS Treatment and Research, Vice-Chair for Research, Neurological Institute, Cleveland Clinic. Dr. Fox has served as a paid consultant to Actelion Pharmaceuticals Ltd and Janssen as a member of the ponesimod Advisory Board.

PONVORY™ has a proven safety profile and was generally well-tolerated over multiple clinical studies totaling more than 10 years, with overall adverse event rates similar to placebo in the Phase 2 and teriflunomide in the Phase 3 trials.^3,4,5,8 The most common adverse events observed in the Phase 3 trial in PONVORY™-treated patients were upper respiratory infection, hepatic transaminase elevation (abnormal liver tests) and hypertension (high blood pressure).⁸

"Every person with multiple sclerosis is affected differently, given variability in both the underlying disease and emerging symptoms. Continued innovation in this space is critical, and we're committed to meeting patients' evolving healthcare needs," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. "We are proud to offer PONVORY as a valuable new option for people with MS that may help them gain better control of their disease."

Janssen CarePath offers a comprehensive support program that helps patients get started on PONVORY™ and stay on track. Janssen CarePath provides information on insurance coverage, potential out-of-pocket costs and treatment support, and identifies options that may help make treatment more affordable, including the Janssen CarePath Savings Program for commercially insured patients who are eligible. For patients who are prescribed PONVORY™, the Wellness Companion Program by Janssen CarePath provides patients with one-on-one education to help them get started and continue treatment.

About the Phase 3 Study⁸
The Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial was a head-to-head, prospective, multicenter, randomized, double-blind Phase 3 study comparing efficacy, safety and tolerability of PONVORY™ 20 mg versus teriflunomide 14 mg in adults with relapsing MS. The primary endpoint of the study, which included 1,133 participants, was the annualized relapse rate (ARR) from baseline through the study period. The study included several other important efficacy endpoints, including the number of new Gd-enhancing T1 lesions from baseline to Week 108, the number of new or enlarging T2 lesions from baseline to Week 108, and the time to 3-month and 6-month confirmed disability progression.